Pharmaceuticals

Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today

CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2024 will be held inBarcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd("Kelun-Biotech", 6990.HK)will present the following results of its anti-TROP...

2024-09-09 14:27 1323

ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress

ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest c...

2024-09-09 08:25 1799

Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)

HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a ...

2024-09-06 10:10 2084

Chugai Pharma Taiwan wins Social Empowerment and Green Leadership Categories at the Asia Responsible Enterprise Awards 2024

SINGAPORE, Sept. 4, 2024 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2024 honored Chugai Pharma Taiwan as an outstanding business leader that champions sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA ceremony was held i...

2024-09-05 10:47 1565

Veeva Vault CRM Suite to Unlock Greater Customer Centricity with Launch of Service Center

Expanded suite to unify sales, marketing, medical and service through a connected software and data foundation SINGAPORE, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Vault CRM Service Center

2024-09-05 09:00 1815

TraceLink's Magnum Release of its Opus Platform Will Revolutionize Supply Chain Management by Enabling All Businesses to Digitalize their End-to-End Supply Networks

With real-time information from all supply chain partners, Supply Chain Managers can reduce inventory and stock-out while improving service levels and lead times BOSTON, Sept. 4, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the ...

2024-09-04 22:00 1665

LakeShore Biopharma Announces Leadership Transitions

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-04 20:00 1476

Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma

SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-09-04 08:00 4247

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published inNeuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 thera...

2024-09-04 06:57 1909

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays

-  Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. -  Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. -  Nature Awards to lead the application and eva...

2024-09-02 21:00 2260

Frost & Sullivan Released Report: "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies"

SHANGHAI, Sept. 2, 2024 /PRNewswire/ -- Frost & Sullivan released a report, titled "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies". The report explores a global CDMO leading the "The Fourth Revolutionary Wave of Biologics Manufacturing" and pioneering...

2024-09-02 17:20 1744

Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024

SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-09-02 08:23 3497

Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

* European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.[1-3] The safety profil...

2024-08-30 20:44 4253

Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations

* Guardant360® CDx is the first blood-based companion diagnostic to be approved inJapan for the detection of EGFR exon 20 insertion mutations TOKYO, Aug. 30, 2024 /PRNewswire/ -- Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo / Representative Director:Mika Takaki), a leading precision oncolog...

2024-08-30 11:01 3668

Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms

Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, increased by 15.1% YoY HONG KONG, Aug. 29, 2024 /PRNewswire/ ...

2024-08-29 20:42 4028

LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital

TOKYO, Aug. 29, 2024 /PRNewswire/ -- LOTTE Holdings Co., Ltd. ("LOTTE Holdings") is pleased to announce the establishment of a new Healthcare and Biopharmaceutical Corporate Venture Capital ("CVC") dedicated to investing in biopharmaceuticals and next-generation modalities.

2024-08-29 10:00 2073

Necessary Care or Abuse? Unpacking the Reason Behind Overprescription

SINGAPORE, Aug. 29, 2024 /PRNewswire/ -- Have you ever wondered if the ten prescriptions your doctor gave you for a cold are truly necessary? Or is there a more complex issue of abuse happening behind the scenes? Today's Case: Overcharging a 7-Year-Old Somsak (an alias name), a 7-year-old boy fr...

2024-08-29 08:30 2619

Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024

SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-08-29 08:00 2037

Innovent Announces 2024 Interim Results and Business Updates

Strong commercial performance and significant pipeline milestones support sustained growth and innovation SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and com...

2024-08-28 18:42 3146

Everest Medicines Announces Interim Results for First Half of 2024

SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2024 a...

2024-08-28 08:00 2317
1 ... 11121314151617 ... 189

Week's Top Stories